The drug behind Mounjaro and Zepbound slowed tumors in an early mouse study. Obesity is tied to higher breast cancer risk, especially after menopause, so the work is drawing interest.
Recap by typeshit. Post by @science__sphere on Instagram.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Roche is putting $100 million behind an obesity target that looks promising but already has rivals. The shared headline doesn't name the target.
Employers can fund weight loss drugs at a fixed cap instead of open-ended coverage. Large employer coverage fell from 72% to 60% this year, per one survey.
Loading…